Abstract:Objective. Enteric-coated mycophenolate sodium (EC-MPS) is widely used in renal transplant recipients. There is a lack of study on the pharmacokinetics of this drug in children. This study is aimed at developing a population pharmacokinetic model of mycophenolic acid in children who were treated with EC-MPS after renal transplantation and to recommend initial dosage. Methods. Pediatric patients who had undergone renal transplantation and received EC-MPS were included. Data on demographic characteristics, biochemical tests, blood routine examinations, mycophenolic acid plasma concentrations, dosing amount and frequency of EC-MPS, and coadministered medications were retrospective collected from June 2018 to August 2019. Nonlinear mixed effect modeling methods were adopted to develop a population pharmacokinetic model with the data above. Additional data from September 2019 to July 2020 were used to validate the model. Simulations under different dosage regimen were conducted to evaluate the percentage of target attainment (PTA, AUC0-12h 30–60 mg·h/L). Results. A total of 96 pediatric patients aged at 13.3 (range 4.3–18.0) years were included in the modeling group. Data from 32 patients aged at 13.0 (range 3.6–18.3) years were used to validate the model. A one-compartment model with a double extravascular absorption was developed. Body surface area (BSA) was added as a covariate. Simulations showed that for different dosing regimens, the highest percentage of target attainment is around 50%. The best dosing regimen is 180 mg every 48 hours for patients with BSA of 0.22–0.46 m2, 180 mg every 24 hours with BSA of 0.47–0.67 m2, 180 mg every 24 hours with BSA of 0.68–0.96 m2, 360 mg every 24 hours with BSA of 0.97–1.18 m2, 540 mg every 24 hours with BSA of 1.19–1.58 m2, and 360 mg every 12 hours with BSA of 1.59–2.03 m2. Conclusion. BSA could affect the area under curve of mycophenolic acid with the administration of EC-MPS. Considering the inflexibility of the dosage form, future development of smaller amount per tablet suitable for younger children with BSA<1.19 m2 is warranted.

Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics.

Population Pharmacokinetics of Ciclosporin in Chinese Children with Aplastic Anemia: Effects of Weight, Renal Function and Stanozolol Administration

Age Difference of Cyclosporin Dosage in Pediatric Patients

Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients

Population Pharmacokinetics of Cyclosporine in Chinese Children Receiving Hematopoietic Stem Cell Transplantation

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients

Population Pharmacokinetic Study Of Cyclosporine In Hematopoietic Stem Cell Transplant Recipients

Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients

Initial Dosage Optimization of Tacrolimus in Chinese Pediatric Patients Undergoing Kidney Transplantation Based on Population Pharmacokinetics and Pharmacogenetics

Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients.

Population Pharmacokinetics and Initial Dose Optimization of Tacrolimus in Children with Severe Combined Immunodeficiency Undergoing Hematopoietic Stem Cell Transplantation

Optimizing the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels

Population Pharmacokinetics and Pharmacogenomics of Tacrolimus in Chinese Children Receiving a Liver Transplant: Initial Dose Recommendation

Population pharmacokinetics of cyclosporine A in hematopoietic stem cell transplant recipients: A systematic review

Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients

Population Pharmacokinetics Model and Initial Dose Optimization of Tacrolimus in Children and Adolescents with Lupus Nephritis Based on Real-World Data

No Effect of Genetic Polymorphisms on Cyclosporine Pharmacokinetics in Renal Transplant Recipients Based on Nonlinear Mixed Effects Modeling

Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Population Pharmacokinetics and Dosage Optimization of Tacrolimus in Pediatric Patients with Nephrotic Syndrome

Population Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Children after Renal Transplantation and Initial Dosage Recommendation Based on Body Surface Area.